ROS1 - Wikipedia
ROS1 is a receptor tyrosine kinase (encoded by the gene ROS1) with structural similarity to the anaplastic lymphoma kinase (ALK) protein; it is encoded by the c-ros oncogene and was first …
ROS1 and Lung Cancer - American Lung Association
Jul 11, 2025 · The targeted therapy a ROS1-positive patient receives is the same regardless of the very specific type of ROS1 rearrangement they may have. How do you know if you have ROS1-positive …
ROS1-Positive Lung Cancer: Symptoms, Treatment, and More
Sep 3, 2025 · ROS1 positive lung cancer is an aggressive form of lung cancer that often spreads quickly. New, targeted medications can help keep this type of lung cancer from progressing for a …
What is ROS1-positive in lung cancer and how is it treated? - LCFA
A ROS1-positive lung cancer, also known as a ROS1 rearrangement in lung cancer, refers to any lung cancer that tests positive for a fusion in the ROS1 gene. ROS1 rearrangements occur in …
ROS1 Gene - GeneCards | ROS1 Protein | ROS1 Antibody
Nov 14, 2025 · ROS1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase) is a Protein Coding gene. Diseases associated with ROS1 include Cholangiocarcinoma and Lung Cancer Susceptibility 3.
ROS1-dependent cancers - biology, diagnostics and therapeutics
The proto-oncogene ROS1 encodes a receptor tyrosine kinase with an unknown physiological role in humans. Somatic chromosomal fusions involving ROS1 produce chimeric oncoproteins that drive a …
New treatment for ROS1+ non-small cell lung cancer
Jun 25, 2025 · The good news The U.S. Food and Drug Administration (FDA) approved taletrectinib for adults with locally advanced or metastatic ROS1-positive (+) non-small cell lung cancer (NSCLC). …
Selecting First-Line Therapy for ROS1 Fusion–Positive NSCLCs
Jun 4, 2025 · Several ROS1 tyrosine kinase inhibitors (TKIs) have been explored as first-line therapies for patients with advanced <i>ROS1</i> fusion–positive non–small cell lung cancers. Only 3 TKIs …
FDA Approves Taletrectinib for ROS1-Positive NSCLC Treatment
Jun 13, 2025 · With its approval, taletrectinib offers a new therapeutic option alongside existing ROS1 inhibitors such as crizotinib, entrectinib, and repotrectinib, broadening the treatment landscape for …
Repotrectinib Shrinks ROS1-Positive NSCLC Tumors - NCI
Feb 16, 2024 · Treatment with repotrectinib shrank tumors in a substantial number of people with advanced NSCLC with ROS1 fusions, results of the TRIDENT-1 trial show.